Related Experiment Video
Updated: Aug 6, 2026

Blood Circuit Reconstruction in an Abdominal Mouse Heart Transplantation Model
Published on: June 3, 2021
Recombinant factor VIIa use in cardiac surgery--expanding the arsenal therapy for intractable bleeding?
1Department of Cardiothoracic Surgery, Rabin Medical Center, Beilinson Campus, Petach Tikva, 49100 Israel. akogan@clalit.org.il
Abstract:
A 72-year-old patient was admitted for mitral valve replacement because of infective endocarditis. Severe intractable bleeding in the early postoperative period was successfully treated with recombinant activated factor VII (rFVIIa). Thereafter, recovery was uneventful, and the patient was discharged on postoperative day 16. The current clinical aspects and experience of rFVIIa use in cardiac surgery are discussed.
Related Concept Videos
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis III: Interprofessional Care
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

